Targeting Nrf2 may reverse the drug resistance in ovarian cancer

BACKGROUND: Acquired resistance to therapeutic drugs has become an important issue in treating ovarian cancer. Studies have shown that the prevalent chemotherapy resistance (cisplatin, paclitaxel etc.) for ovarian cancer occurs partly because of decreased production of reactive oxygen species within...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Danjie, Hong, Xiaoling, Zhao, Feijie, Ci, Xinxin, Zhang, Songling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890806/
https://www.ncbi.nlm.nih.gov/pubmed/33596893
http://dx.doi.org/10.1186/s12935-021-01822-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890806/
https://www.ncbi.nlm.nih.gov/pubmed/33596893
http://dx.doi.org/10.1186/s12935-021-01822-1

Ejemplares similares